Bristol Expands Fibrosis Pipeline With Galecto Buy Option
This article was originally published in Start Up
Executive Summary
Three-year-old Galecto Biotech on November 3 secured funding and validation from Bristol-Myers Squibb Co. in an option-to-buy deal that could be worth up to $444 million. Galecto’s lead asset, an inhaled inhibitor of galectin-3 in development for idiopathic pulmonary fibrosis, has only just entered human testing. But IPF – and fibrosis more broadly – has become something of a hot-spot.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?